Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert S Stern

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
The Journal of Investigative Dermatology|March 6, 2009
Putting iatrogenic risk in perspective: basal cell cancer in PUVA patients and AustraliansRobert S Stern
The New England Journal of Medicine|November 5, 2025
Oral Psoriasis Therapy - For Whom and at What Cost and Risk?Robert S Stern
The New England Journal of Medicine|June 29, 2012
Clinical practice. Exanthematous drug eruptionsRobert S Stern
The Journal of Investigative Dermatology|April 28, 2005
Proportion of lifetime UV dose received by age 18, what Stern et al actually said in 1986Robert S Stern
Archives of Dermatology|March 17, 2010
Prevalence of a history of skin cancer in 2007: results of an incidence-based modelRobert S Stern
The Journal of Investigative Dermatology|November 17, 2007
Chronic medication use and inflammatory skin diseases: the power and limitations of the case-control studyRobert S Stern
The Journal of Investigative Dermatology|November 1, 2013
Response to Rogers et alRobert S Stern
JAMA|October 17, 2014
Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysisRobert S Stern
Journal of the American Academy of Dermatology|September 18, 2010
Poor metrics and lost opportunityRobert S Stern
Archives of Dermatology|September 20, 2006
Topical calcineurin inhibitors labeling: putting the "box" in perspectiveRobert S Stern
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
The Journal of Investigative Dermatology|March 6, 2009
Putting iatrogenic risk in perspective: basal cell cancer in PUVA patients and AustraliansRobert S Stern
The New England Journal of Medicine|November 5, 2025
Oral Psoriasis Therapy - For Whom and at What Cost and Risk?Robert S Stern
The New England Journal of Medicine|June 29, 2012
Clinical practice. Exanthematous drug eruptionsRobert S Stern
The Journal of Investigative Dermatology|April 28, 2005
Proportion of lifetime UV dose received by age 18, what Stern et al actually said in 1986Robert S Stern
Archives of Dermatology|March 17, 2010
Prevalence of a history of skin cancer in 2007: results of an incidence-based modelRobert S Stern
The Journal of Investigative Dermatology|November 17, 2007
Chronic medication use and inflammatory skin diseases: the power and limitations of the case-control studyRobert S Stern
The Journal of Investigative Dermatology|November 1, 2013
Response to Rogers et alRobert S Stern
JAMA|October 17, 2014
Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysisRobert S Stern
Journal of the American Academy of Dermatology|September 18, 2010
Poor metrics and lost opportunityRobert S Stern
Archives of Dermatology|September 20, 2006
Topical calcineurin inhibitors labeling: putting the "box" in perspectiveRobert S Stern
Pageof 7